|
|
|
| A case of Sjögren’s syndrome complicated with pigmented villonodular synovitis and literature review |
| LI Size1 ZHOU Weijian2 YIN Shiyun2 GUAN Xin1 FENG Yaqiong1 DING Shan2 CHEN Yanlin2 TANG Xiaohu2 |
1.The First School of Clinical Medicine, Yunnan University of Chinese Medicine, Yunnan Province, Kunming 650011, China;
2.Department of Rheumatology, the First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Yunnan Province, Kunming 650021, China
|
|
|
|
Abstract Sjögren’s syndrome (SS) belongs to an inflammatory autoimmune disease mainly involving exocrine glands, in addition to exocrine gland manifestations such as dry eyes and dry mouth, pulmonary interstitial fibrosis is common clinically, and pigmented villonodular synovitis (PVNS) is rare. PVNS is a rare disease in clinical practice, with dual characteristics of inflammation and tumor, non-specific clinical manifestations, frequent joint swelling, pain, and limited activity at the onset of disease. Clinical misdiagnosis of PVNS is easy, pathological examination is the gold standard for diagnosis of PVNS, and surgical resection of the affected joint synovium is the main treatment for PVNS. Radiotherapy can be used as postoperative adjuvant therapy for this disease. In this paper, a patient with left lower limb distension and pain as the primary clinical manifestations accompanied by dry eyes and mouth and recurrent bloody joint effusion in the left knee was reported. After histomathological examination, SS and PVNS were confirmed to be present at the same time. The previous literature was reviewed in order to provide reference for clinical diagnosis and treatment of this disease with integration of Chinese and western medicine.
|
|
|
|
|
|
[1] 白雪娇，柏志义，王海瑜，等.基于中国知网数据库文献分析干燥综合征的研究热点[J].中国医药导报，2021，18（19）：13-16，26.
[2] 葛均波，徐永键，王辰.内科学[M].北京：人民卫生出版社，2018：829-830.
[3] 唐子荣，杨明，程华茂，等.色素沉着绒毛结节性滑膜炎1例并文献复习[J].华中科技大学学报（医学版），2020，49（3）：351-353.
[4] 仲建全，魏东，韩副刚，等.色素沉着绒毛结节性滑膜炎MRI表现及其病理基础[J].中国医学计算机成像志，2010， 16（6）：512-516.
[5] Bernthal NM，Ishmael CR，Burke ZDC. Management of Pigmented Villonodular Synovitis （PVNS）：an Orthopedic Surgeon’s Perspective [J]. Curr Oncol Rep，2020，22（6）：63.
[6] Ottaviani S，Ayral X，Dougados M，et al. Pigmented villonodular synovitis：a retrospective single-center study of 122 cases and review of the literature [J]. Semin Arthritis Rheum，2011，40（6）：539-546.
[7] 李红松，朱光昭，吕柳，等.13例干燥综合征合并胰腺炎患者临床特征分析[J].中国医药导报，2021，18（19）：95- 97.
[8] Jendrissek KA，Hotfiel T，Swoboda B，et al. Pigmented villonodular synovitis.A rare differential diagnosis of synovial joint swelling [J]. Z Rheumatol，2016；75（2）：157-165.
[9] 谢磊，黄爱苹，薛纯纯，等.针刀镜治疗原发性肩关节周围炎的临床效果[J].中国医药导报，2021，18（36）：135- 138.
[10] Gouin F，Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor （formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis）[J]. Orthop Traumatol Surg Res，2017，103（1S）：S91-S97.
[11] Cupp JS，Miller MA，Montgomery KD，et al. Translocation and expression of CSF1 in pigmented villonodular synovitis，tenosynovial giant cell tumor，rheumatoid arthritis and other reactive synovitides [J]. Am J Surg Pathol，2007，31（6）：970-976.
[12] West RB，Rubin BP，Miller MA，et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells [J]. Proc Natl Acad Sci U S A，2006，103（3）：690-695.
[13] Burton TM，Ye X，Parker ED，et al. Burden of Illness Associated with Tenosynovial Giant Cell Tumors [J]. Clin Ther，2018，40（4）：593-602.e1.
[14] Ho J，Peters T，Dickson BC，et al. Detection of CSF1 rearrangements deleting the 3’ UTR in tenosynovial giant cell tumors [J]. Genes Chromosomes Cancer，2020，59（2）：96- 105.
[15] 李伟华，胡鹏，毕树雄.色素沉着绒毛结节性滑膜炎的研究进展[J].国际骨科学杂志，2021，42（1）：40-44.
[16] Sistla RJVSV，Afroz T. Malignant Pigmented Villonodular Synovitis-A Rare Entity [J]. J Orthop Case Rep，2014，4（4）：9-11.
[17] Alexiev BA，Tumer Y，Yang GY. Malignant tenosynovial giant cell tumor with CDKN2A/B genomic alteration：a histological，immunohistochemical，and molecular study [J]. Hum Pathol，2017，63：144-148.
[18] Zhao L，Zhou K，Hua Y，et al. Multifocal pigmented villonodular synovitis in a child：A case report [J]. Medicine （Baltimore），2016，95（33）：e4572.
[19] ?覶evik HB，Kayahan S，Eceviz E，et al. Tenosynovial giant cell tumor in the foot and ankle [J]. Foot Ankle Surg，2020，26（6）：712-716.
[20] 栗二毛，张斌青，郭会利.膝关节弥漫性色素沉着绒毛结节性滑膜炎的MRI影像学特征[J].风湿病与关节炎，2017，6（1）：33-35.
[21] 谭源满，吴艳，叶思婷，等.色素沉着绒毛结节性滑膜炎与腱鞘巨细胞瘤的MRI诊断[J].医学影像学杂志，2017， 27（1）：125-127，157.
[22] Yang B，Liu D，Lin J，et al. Surgical treatment of diffuse pigmented villonodular synovitis of the knee [J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao，2015，37（2）：234-239.
[23] Brahmi M，Vinceneux A，Cassier PA. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis：Targeting the CSF1/CSF1R Axis [J]. Curr Treat Options Oncol，2016，17（2）：10.
[24] Mollon B，Lee A，Busse JW，et al. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee：an individual patient meta-analysis [J]. Bone Joint J，2015，97-B（4）：550-557.
[25] 陈超勇，黄连花，李鹏，等.关节镜配合桃红四物汤治疗膝关节色素沉着绒毛结节性滑膜炎36例[J].河南中医，2016，36（4）：709-711.
[26] Tap WD，Gelderblom H，Palmerini E，et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour （ENLIVEN）：a randomised phase 3 trial [J]. Lancet，2019，394（10197）：478-487.
[27] Monestime S，Lazaridis D. Pexidartinib（TURALIOTM）：The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor [J]. Drugs R D，2020，20（3）：189-195. |
|
|
|
